Euglycemic diabetic ketoacidosis: another masquerader!
Keywords:Empagliflozin, SGLT2 inhibitor, Type 2 diabetes, Euglycemic ketoacidosis
AbstractEuglycemic ketoacidosis is defined by the triad of euglycemia, metabolic acidosis and ketonemia or ketonuria. In the current era of diabetic management, it is a serious concern with the usage of sodium glucose co-transporter 2 (SGLT2) inhibitors potentiated by a number of precipitating agents. Empagliflozin though a novel oral hypoglycemic agent in this category may also lead to this potential complication. Here we report a 59 year old male, type 2 diabetic who was on empagliflozin and presented with euglycemic ketoacidosis after a binge of alcohol.
Rosenwasser RF, Sultan S, Sutton D, Choksi R, Epstein BJ. SGLT 2 inhibitors and their potential in treatment of Diabetes, Diabet Metabol Syndrome Obes. 2013;6:453-67.
U.S. Food and Drug Administration. Drug Safety Communication: FDA warns that SGLT2 inhibitors for diabetes may result in a serious condition of too much acid in the blood, 2015. Available at: http://www.fda.gov/downloads/Drugs/Drugsafety/UCM446954. Accessed on 05 October 2018.
Munro JF, Campbell IW, McCuish AC, Duncan LJ. Euglycaemic diabetic ketoacidosis. Br Med J. 1973;2:578-80.
Miles JM, Gerich JE. Glucose and ketone body kinetics in diabetic ketoacidosis. Clin Endocrinol Metab. 1983;12:303-19.
Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes (EMPA-REG OUTCOME). New Engl J Med. 2015;373:2117-28.
Rosenstock J, Ferrannini E. Euglycemic diabetic ketoacidosis: a predictable, detectable, and preventable safety concern with SGLT2 inhibitors. Diab Care. 2015;38(9):1638-42.
Gammons T, Counselman FL. Sodium-glucose cotransporter-2 induced diabetic ketoacidosis with minimal hyperglycemia. Clin Practice Cases Emerg Med. 2018;2(1):47-50.
Candelario N, Wykretowicz J. The DKA that wasn't: a case of euglycemic diabetic ketoacidosis due to empagliflozin. Oxford Med Case Report. 2016;2016(7):144-6.